Transformational Workflow Solution Offers
Real-Time Imaging of Tissue Samples, Resulting in Major Cost and Time Savings
MARLBOROUGH, Massachusetts,
Jan. 9, 2018 /PRNewswire/
-- Hologic, Inc. (Nasdaq: HOLX) today announced it has
obtained a CE Mark in Europe for
the Brevera® breast biopsy system with
CorLumina® imaging technology, a groundbreaking
real-time breast biopsy and verification system that improves the
patient experience and streamlines the biopsy process from start to
finish. The first-of-its-kind Brevera system is designed to
increase biopsy accuracy with real-time imaging that delivers
valuable information at the point of care, enabling clinicians to
make informed decisions with confidence.
The Brevera system is the world's first and only breast biopsy
solution to combine tissue acquisition, real-time imaging, sample
verification and advanced post-biopsy handling in one, integrated
system. Designed for 2D and 3D™ breast biopsy, the innovative
system allows clinicians to perform fast and efficient procedures
that save costs and improve the patient
experience.1 The new product represents
another major advance in Hologic's ongoing efforts to improve
patient satisfaction and workflow in the biopsy suite.
Until now, radiologists performing stereotactic breast biopsy
procedures to diagnose breast cancer were often required to leave
the patient under compression while they moved to another room to
image and verify tissue samples. This leads to lengthy procedure
times and anxious, uncomfortable patients, and can interrupt
facility screening schedules. With the Brevera system, radiologists
are able to obtain and image tissue samples in the procedure room
in just a few seconds, potentially saving up to 10 minutes per
patient and cutting the procedure time by up to 25
percent.2
"The Brevera system is a major breakthrough that transforms the
breast biopsy procedure as we know it," said Jan Verstreken,
Hologic's President for EMEA and Canada. "Clinicians are now able to image and
verify tissue samples in real-time in the procedure room, leading
to fast procedure times and an improved experience for women,
without compromising accuracy or outcomes. The Brevera system is
yet another example of Hologic's dedication to developing products
that are designed to better meet the needs of our customers and
their patients."
In addition to saving facility resources and clinician time
during a breast biopsy procedure, the Brevera system's proprietary
CorLumina imaging technology helps enhance workflow across multiple
departments within a health system. The technology automates the
tissue sample collection and separation process, which allows
patient tissue to be sent to pathology with little or no manual
handling, and also protects the integrity of samples. The system
also features PACS integration for advanced image sharing and
transfer of patient records.
The Brevera system is designed for use with Hologic's Affirm®
prone biopsy system, Affirm® breast biopsy guidance system, and
MultiCare® Platinum system, as well as most upright and prone
systems on the market.
About Hologic, Inc.
Hologic, Inc. is an innovative
medical technology company primarily focused on improving women's
health and well-being through early detection and treatment. For
more information on Hologic, visit www.hologic.com.
Hologic, 3D, Affirm, Brevera, CorLumina, MultiCare, The Science
of Sure, and associated logos are trademarks and/or registered
trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may
contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated
in any particular manner with respect to an individual patient, as
the actual effect of the use of the products can only be determined
on a case-by-case basis. In addition, there can be no assurance
that these products will be commercially successful or achieve any
expected level of sales. Hologic expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such data or statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
Media Contact:
Jane
Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael
Watts
+1 858.410.8588
michael.watts@hologic.com
______________________________
1 3D biopsy only when used with the Affirm breast biopsy
system.
2 2015 Kadence International survey of 200 healthcare
professionals.